Dr. Rachel Tate uptoTate
3 years 10 months ago
"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD
Eric Dein ericdeinmd
3 years 10 months ago
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Lab Domains:
LAC not always feasible to recheck
aCL, aB2GP IgG higher risk, higher titers (>40U)
@RheumNow https://t.co/rcQaqrtDN5
Eric Dein ericdeinmd
3 years 10 months ago
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Obstetric domain redefined
Added:
⭐️Cardiac thickening/vegetation
⭐️Thrombocytopenia
@Rheumnow https://t.co/Me2jrnvalU
Eric Dein ericdeinmd
3 years 10 months ago
13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22
Novel Aspects
Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles
Microvasc - Suspected/Established
@RheumNow https://t.co/M8NWRSyH4p
Richard Conway RichardPAConway
3 years 10 months ago
Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccuracy. 78% authors >= undisclosed/underreported COI. Worse in clinical trials 85% @RheumNow #ACR22 Abstr#1267 https://t.co/dmqp3sj11f https://t.co/UXQgUCcGWb
Dr. John Cush RheumNow
3 years 10 months ago
Frailty in Vasculitis
Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22 Convergence.
https://t.co/aMpcBhT5yE https://t.co/rPgA19dT0W
Richard Conway RichardPAConway
3 years 10 months ago
Henry @EBRheum et al. Less than 1 in 6 recommendations from ACR/EULAR informed by comparative effectiveness RCT. Many receive strong recommendation despite low/very low LOE. @RheumNow #ACR22 Abstr#1284 https://t.co/1MUM8qiwDl https://t.co/KJcf7rBQAU
Richard Conway RichardPAConway
3 years 10 months ago
Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3% used IL6i, 36% DMARD. DM and morbid obese more likely to use. Women, older, and using IL6i/DMARD more likely to have GC>1 year @RheumNow #ACR22 Abstr#1546 https://t.co/Imjsgyo49j https://t.co/8E5Rj5d7Pz
Richard Conway RichardPAConway
3 years 10 months ago
Arora @BichileT et al. PJP prophylaxis practice among nephrologists and rheumatologists @RheumNow #ACR22 Abstr#1282 https://t.co/3VyJR6k76U https://t.co/VM5rnbmv9h
Much has been written about tapering medications in rheumatic diseases, often due to high costs of medications, a desire to avoid side effects and patient preference to take less medications (especially if they have side effects).
This is countered by something we all know: medications not taken don’t work, and those that are frequently missed may not provide optimal outcomes for the majority of patients.
Mike Putman EBRheum
3 years 10 months ago
Another poster from my research group!
Investigated recommendations in ACR/EULAR guidelines
<1/6th informed by head 2 head RCT
We need more comparative effectivness research!
#ACR22 @RheumNow #1284 https://t.co/HQoeKj0cxy
